Insider Transactions in Q2 2024 at Exact Sciences Corp (EXAS)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 13
2024
|
Michael J Barber |
BUY
Grant, award, or other acquisition
|
Direct |
5,444
+50.0%
|
-
|
|
Jun 13
2024
|
Shacey Petrovic |
BUY
Grant, award, or other acquisition
|
Direct |
5,444
+25.49%
|
-
|
|
Jun 13
2024
|
D Scott Coward |
BUY
Grant, award, or other acquisition
|
Direct |
5,444
+9.8%
|
-
|
|
Jun 13
2024
|
Daniel J Levangie |
BUY
Grant, award, or other acquisition
|
Direct |
5,444
+16.08%
|
-
|
|
Jun 13
2024
|
Katherine S Zanotti |
BUY
Grant, award, or other acquisition
|
Direct |
5,444
+7.21%
|
-
|
|
Jun 13
2024
|
Paul J Clancy |
BUY
Grant, award, or other acquisition
|
Direct |
5,444
+21.27%
|
-
|
|
Jun 13
2024
|
Kathleen Sebelius |
BUY
Grant, award, or other acquisition
|
Direct |
6,889
+17.77%
|
-
|
|
Jun 13
2024
|
James Edward Doyle |
BUY
Grant, award, or other acquisition
|
Direct |
5,444
+8.92%
|
-
|
|
May 01
2024
|
Kevin T Conroy President and CEO |
SELL
Open market or private sale
|
Direct |
1,155
-0.1%
|
$69,300
$60.15 P/Share
|
|
May 01
2024
|
Jacob A Orville EVP, GM, Screening |
SELL
Open market or private sale
|
Direct |
102
-0.7%
|
$6,120
$60.15 P/Share
|
|
May 01
2024
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
102
-0.14%
|
$6,120
$60.15 P/Share
|
|
May 01
2024
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Open market or private sale
|
Direct |
110
-0.82%
|
$6,600
$60.15 P/Share
|
|
May 01
2024
|
Jeffrey Thomas Elliott Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
136
-1.14%
|
$8,160
$60.15 P/Share
|
|
May 01
2024
|
James Herriott SVP, General Counsel & Sec |
SELL
Open market or private sale
|
Direct |
30
-0.3%
|
$1,800
$60.15 P/Share
|
|
May 01
2024
|
Everett Cunningham Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
136
-0.29%
|
$8,160
$60.15 P/Share
|
|
May 01
2024
|
D Scott Coward |
SELL
Open market or private sale
|
Direct |
67
-0.15%
|
$4,020
$60.15 P/Share
|
|
Apr 30
2024
|
Kevin T Conroy President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
3,197
+0.14%
|
$47,955
$15.01 P/Share
|
|
Apr 30
2024
|
Jacob A Orville EVP, GM, Screening |
BUY
Grant, award, or other acquisition
|
Direct |
218
+1.48%
|
-
|
|
Apr 30
2024
|
Sarah Condella EVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
926
+0.63%
|
$13,890
$15.01 P/Share
|
|
Apr 30
2024
|
Brian Baranick EVP, GM, Precision Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
218
+1.6%
|
-
|
|
Apr 30
2024
|
Jeffrey Thomas Elliott Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
998
+4.06%
|
$14,970
$15.01 P/Share
|
|
Apr 30
2024
|
James Herriott SVP, General Counsel & Sec |
BUY
Grant, award, or other acquisition
|
Direct |
771
+3.68%
|
$11,565
$15.01 P/Share
|
|
Apr 30
2024
|
Everett Cunningham Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
999
+1.05%
|
$14,985
$15.01 P/Share
|
|
Apr 30
2024
|
D Scott Coward |
BUY
Grant, award, or other acquisition
|
Direct |
218
+0.49%
|
-
|
|
Apr 02
2024
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Open market or private sale
|
Direct |
924
-6.56%
|
$72,996
$79.43 P/Share
|
|
Apr 01
2024
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
2,000
-2.71%
|
$140,000
$70.0 P/Share
|